TENAYA THERAPEUTICS I

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

15 5 2025 20:00:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

13 5 2025 07:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

07 5 2025 15:05:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

24 4 2025 13:07:47 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

31 3 2025 09:00:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

24 3 2025 07:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session

19 3 2025 07:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

10 3 2025 15:05:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Pricing of Public Offering

03 3 2025 22:19:31 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Proposed Public Offering

03 3 2025 15:10:10 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

03 3 2025 07:00:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

03 2 2025 07:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

13 1 2025 08:16:36 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

17 12 2024 06:00:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

16 12 2024 15:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

25 11 2024 07:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

19 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

06 11 2024 15:05:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

17 10 2024 15:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

03 9 2024 07:30:00 提供 Nasdaq GlobeNewswire